Introduction {#s01}
============

The lymphatic system returns fluid and macromolecules from the interstitial space back to the blood circulation against a net hydrostatic pressure gradient. This is achieved through a combination of extrinsic forces such as tissue compression (i.e., skeletal or smooth muscle contractions) and the intrinsic lymphatic pump generated by the active contractions of the lymphatic collecting vessels ([@bib63]; [@bib64]). Spontaneous contractile activity is characterized by the rhythmic, entrained, and rapid contractions of the lymphatic muscle layer, with shortening velocities that approach those of striated muscle ([@bib66]). Lymphatic contractile activity is impaired in lymphedema patients ([@bib41]), in which peripheral lymphatic vessels display weak and/or irregular contractions. Our understanding of the molecular and ionic mechanisms underlying the initiation and regulation of spontaneous lymphatic contractions remains limited, precluding the use of pharmaceutical therapy to target the dysfunctional lymphatic pump.

Similar to arteries and arterioles, lymphatic collecting vessels integrate physical and biochemical stimuli ([@bib63]), such as pressure and vasoactive agents ([@bib12], [@bib13]), to regulate their contractile activity. Lymphatic collecting vessels are highly sensitive to transmural pressure ([@bib20]; [@bib63]) such that contraction frequency can increase 10-fold in response to less than a 10-cm H~2~O change in transluminal pressure ([@bib43]). The mechanism underlying this pressure-dependent phenomenon is likely electrical in nature as lymphatic contractions are driven by action potentials that trigger Ca^2+^ influx through voltage-gated L-type Ca^2+^ channels (LTCCs; [@bib33]; [@bib65]). This pressure-dependent contraction frequency suggests a stretch-sensitive mechanism that increases the rate at which an action potential is initiated; however, this process has not been fully defined. The current paradigm regarding the initiation of lymphatic contraction is based on membrane potential (V~m~) recordings performed primarily in guinea pig and sheep ([@bib54]; [@bib51]; [@bib55]), and posits a role for the summation of stochastic, 1--2 mV spontaneous transient depolarizations, derived from an undefined calcium activated chloride channel (CaCC), to reach a critical threshold to fire an action potential ([@bib54]; [@bib56]). In contrast to the hypothesis in which spontaneous transient depolarizations are central, recent V~m~ recordings from lymphatic collecting vessels in rat ([@bib57]), sheep ([@bib1]), and mice ([@bib65]) have instead revealed a near-linear diastolic depolarization that drives action potential generation. Regardless of the mechanism, spontaneous transient depolarization summation or linear diastolic depolarization, these initiation sequences may share a similar ionic basis involving a CaCC current (I~ClCa~) as the rate-limiting step in regulating lymphatic contraction frequency ([@bib54]; [@bib28]; [@bib36]; [@bib51]; [@bib1]; [@bib56]; [@bib38]). However, the identity of the CaCC is unknown.

Anoctamin 1 (Ano1) has been identified as the canonical CaCC in other tissues ([@bib6]; [@bib46]; [@bib62]) and has been linked to both resting V~m~ and vessel tone ([@bib4]) in the blood vascular system. We tested the hypothesis that Ano1 is critical to pressure-sensitive contraction frequency of the peripheral murine internodal inguinal axillary lymphatic collecting vessel (IALV), using both molecular and functional techniques with a combination of inducible or constitutive smooth muscle--targeted Ano1 knockouts (KOs) and pharmaceutical inhibition with benzbromarone. We used sharp electrode recordings to determine the role of Ano1 in the excitability of murine lymphatic smooth muscle and its contribution to the lymphatic muscle action potential. Additionally, we expressed the genetically encoded Ca^2+^ indicator GCaMP6f in lymphatic smooth muscle to test if Ano1 alters the Ca^2+^ influx through voltage-dependent Ca^2+^ channels during the lymphatic action potential. The results reveal a critical role for Ano1 in the linear diastolic depolarization phase that regulates lymphatic pacemaking. These findings shed light on the ionic basis for pressure-dependent contraction frequency and auto-rhythmicity of lymphatic muscle.

Materials and methods {#s02}
=====================

Mice {#s03}
----

WT male mice (15--35 g) on the C57BL/6J background, ROSA26 mT/mG fluorescent Cre recombinase activity reporter mice ([@bib39]; strain 007676), the constitutively expressed smMHC^Cre/eGFP^ ([@bib61]; strain 007742), and the genetically encoded Ca^2+^ sensor GCaMP6f ([@bib9]; strain 028865) were purchased from The Jackson Laboratory. The y chromosome--linked tamoxifen inducible SMMHC-CreER^T2^ mice ([@bib60]) were a gift from S. Offermanns, Max-Planck-Intstitut fur Herz-und Lungendforschung, Bad Nauheim, Germany. c-KitCreER^T2^ mice ([@bib26]) were provided by D. Saur, Technical University of Munich, Munich, Germany. An Ano1 floxed mouse was generated at the University of Tennessee, Knoxville, TN, by Jonathan H. Jaggar, and was bred to SMMHC-CreER^T2^ mice, c-KitCreER^T2^ mice, and smMHC^Cre/eGFP^ mice to generate the following genotypes: SMMHC-CreER^T2^;Ano1fl/fl, c-KitCreER^T2^;Ano1fl/fl, and smMHC^Cre/eGFP^;Ano1fl/fl. Upon induction of the Cre with tamoxifen injections, we refer respectively to these mice as SMMHC-CreER^T2^-Ano1KO, c-KitCreER^T2^-Ano1KO, and smMHC^Cre/eGFP^-Ano1KO mice. Mice harboring GCaMP6f were also bred with SMMHC-CreER^T2^;Ano1fl/fl mice to generate the SMMHC-CreER^T2^-GCaMP6f and SMMHC-CreER^T2^G-CaMP6f-Ano1KO mice. In addition to these models, an Ano1-GFP reporter mouse, a doxycycline-inducible SMArTTa-tetOCre mouse, and a genetically distinct Ano1 floxed mouse generated at the University of California, San Francisco, San Francisco, CA, ([@bib44]) were provided by Jason Rock (Boston University, Boston, MA). The doxycycline-induced SMArTTa-tetOCre;Ano1fl/fl mice are herein referred to as SMArTTa-tetOCre-Ano1KO. We collectively refer to the combination of SMMHC-CreER^T2^-Ano1KO, smMHC^Cre/eGFP^-Ano1KO, and SMArTTa-tetOCre-Ano1KO mice as Ano1^smKO^ in passing. Genomic DNA was extracted from tail clips using the HotSHOT method ([@bib53]). Genotypes were determined by PCR with PCR Super Master Polymerase Mix (B46019; Bimake) according to the provider's instructions. All animal protocols were approved by the University of Missouri Animal Care and Use Committee and conformed to the US Public Health Service policy, 1996, for the humane care and use of laboratory animals.

IALV isolation {#s04}
--------------

IALVs and popliteal lymphatic vessels were isolated as previously described ([@bib7]; [@bib65]). In brief, mice were anaesthetized with pentobarbital sodium (60 mg/kg intraperitoneal (i.p.); Nembutal) and placed on a heating pad. The IALV was isolated by a midline dorsal incision and retraction of the dorsal skin that revealed the thoracoepigastric vein and the IALV running caudally along the skin connecting the inguinal and axillary lymph nodes. The perivascular adipose and connective tissue containing the IALV were excised from the retracted skin, and the mouse was euthanized via KCl overdose. After removal, the dissected tissue was pinned to a Sylgard dish in warmed Krebs buffer, and the IALV was carefully cleaned using fine forceps and microscissors. In some protocols, the entire length(s) of the IALV(s) from the conjoined inguinal and axillary nodes from either one or both sides of the mouse was/were collected for RNA purification, protein collection, immunofluorescence, and smooth muscle cell dispersion/isolation. Half lymphangion sections (i.e., containing one lymphatic valve) were used for contractile myograph, sharp electrode impalements, and Ca^2+^ imaging experiments. Popliteal vessels were isolated as previously described ([@bib43]).

Cre induction protocols {#s05}
-----------------------

SMArTTa-tetOCre-Ano1KO mice were induced by five consecutive daily i.p. injections of 2 mg of doxycycline (4 mg/ml; sterile saline). SMMHC-CreER^T2^ Ano1KO, c-KitCreER^T2^ Ano1KO, and Ano1fl/fl control mice were induced by five consecutive i.p. injections of 1 mg tamoxifen (10 mg/ml; safflower oil). For some experiments, SMMHC-CreER^T2^-GCaMP6f and SMMHC-CreER^T2^-GCaMP6f-Ano1KO mice were induced through feeding tamoxifen-infused rodent chow (500 mg/kg; TD130857; Envigo) over a 1-wk period. Mice were given a 2-wk recovery period following the last day of injection or feeding to clear the tamoxifen.

### Determination of recombination in IALVs {#s06}

Initially, we bred each inducible Cre line to the fluorescent reporter ROSA26mT/mG, in which Cre recombinase activity switches the expression of td-tomato to GFP, to determine the fidelity and efficacy of the recombinase activity in the lymphatic collecting vessel. SMMHC-CreER^T2^;ROSA26mT/mG, c-KitCreER^T2^;ROSA26mT/mG, and SMArTTa-tetOCre;ROSA26 mT/mG mice were used to identify the cell populations with Cre activity driven by the induction protocol, and to assess recombination efficiency within the lymphatic muscle layer. IALVs were isolated for confocal imaging and immunofluorescence, and recombination efficiency was determined by the percentage of double-positive GFP and smooth muscle actin (SMA) cells. Additionally, for c-KitCreER^T2^ROSA26mT/mG mice, small sections of the jejunum (5 mm) were excised and rinsed of their luminal contents using cold Ca^2+^-free Krebs buffer to prevent tissue movement. The section of intestine was cut open and pinned down onto a 35-mm dish coated in Sylgard and maintained in cold Ca^2+^-free Krebs buffer. The mucosa and sub-mucosa layers were then carefully dissected away. The remaining tissue was imaged using a fluorescence macroscope (Zeiss Axiozoom.v16) at 112× to reveal the GFP^+^ interstitial cells of Cajal network.

Lymphatic muscle cell (LMC) dissociation and collection for patch clamp {#s07}
-----------------------------------------------------------------------

LMCs were collected by enzymatic dissociation of 1--2 IALV segments. The dissected IALVs were cleaned in Krebs buffer: 146.9 NaCl, 4.7 KCl, 2 CaCl~2~•2H~2~O, 1.2 MgSO~4~, 1.2 NaH~2~PO~4~•H~2~O, 3 NaHCO~3~, 1.5 NaHEPES, and 5 d-glucose, pH 7.4, at 37°C. Cleaned IALV segments were transferred to a 1-ml tube of low-Ca^2+^ PSS containing (in mM) 137 NaCl, 5.0 KCl, 0.1 CaCl~2~, 1.0 MgCl~2~, 10 HEPES, 10 glucose, and 1 mg/ml BSA at room temperature for 10 min. The solution was decanted and replaced with a similar solution containing 26 U/ml papain (Sigma-Aldrich) and 1 mg/ml dithioerythritol. The IALVs were incubated for 30 min at 37°C with occasional agitation, then transferred to a new tube containing low-Ca^2+^ physiological saline solution (PSS) containing 1.95 collagenase H (U/ml; C8051; Sigma-Aldrich) and 1.8 mg/ml collagenase F (C7926; Sigma-Aldrich), and incubated for 3 to ∼5 min at 37°C. After further digestion, the remaining fragments were rinsed two or three times with low Ca^2+^ PSS without BSA and gently triturated using a fire-polished Pasteur pipette to release single cells. Isolated LMCs were stored in ice-cold isolation medium until use. Once they settled on the bottom of the chamber, LMCs were identified by their spindle-like morphology and used for whole-cell patch clamping. In some cases, LMCs were collected via micropipette for reverse transcription (RT)-PCR analysis. We also used IALVs dissected from induced SMMHC-CreER^T2^-ROSA26mT/mG mice for fluorescence-activated cell sorting of LMCs. The above digestion protocol was modified slightly by the addition of 100 µl of 10 mg/ml elastase (LS00635; Worthington) to the collagenase H and F cocktail. The digested vessel was then spun down at 1,000 rpm for 4 min and rinsed with low-Ca^2+^ PSS. This washing process was repeated two more times before titration. The vessel cell suspension was then passed through a Falcon cap strainer (80 µm) and resuspended in low-Ca^2+^ PSS for sorting. Sorted GFP^+^ LMCs cells were collected in RNA isolation buffer and immediately processed for RNA purification.

RT-PCR {#s08}
------

Total RNA was extracted from dissected and cleaned IALVs, and flash-frozen whole mouse brain or whole kidney (positive controls), using the Arcturus PicoPure RNA isolation kit (Thermo Fisher Scientific) following the manufacturer's instructions. On-column deoxyribonuclease digestion (QIAGEN) was performed to eliminate contamination of the samples from genomic DNA. Complementary DNA (cDNA) synthesis was performed with the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific) using oligonucleotide (dT) and random hexamer priming following the manufacturer's protocol. PCR was performed in a reaction mixture containing first-strand cDNA as the template, 2 mM MgCl~2~, 0.25 µM primers, 0.2 mM deoxynucleotide triphosphates, and GoTaq Flexi DNA polymerase (Promega). The PCR program comprised an initial denaturation step at 95°C for 4 min, followed by 35 repetitions of the following cycle: denaturation (94°C, 30 s), annealing (30 s), and extension (72°C, 30 s). This was followed by a final elongation step for 5 min at 72°C. PCR amplification products were separated on a 2% agarose gel by electrophoresis, stained with SYBR-Safe (Thermo Fisher Scientific), and visualized by UV trans-illumination. All primers were designed to amplify an intron-spanning region. Our designed endpoint RT-PCR primer sequences and the quantitative PCR (qPCR) primers and probes purchased from IDT are listed in [Table 1](#tbl1){ref-type="table"}.

###### Primers used for qPCR and RT-PCR

  **qPCR primers**                                                                                   
  ---------------------- ------------------- ------------ ------------------------------------------ --------------------------------
  *Ano1*                 NM_178642                        IDT Mm.PT.58.12522115                      Mouse Ano1 TaqMan probe IDT
  *SMA*                  NM_007392                        IDT Mm.PT.58.16320644                      Mouse α-actin TaqMan probe IDT
  *β-Actin*              NM_007393                        IDT Mm.PT.58.33257376.gs                   Mouse Actb TaqMan probe IDT
  **End point RT-PCR**                                                                               
  **Gene**               **Accession no.**   **Strand**   **Sequence** / **Catalog Number**          **Amplicon (bp)**
  *Ano1*                 NM_178642           F            5′-GGC​ATT​TGT​CAT​TGT​CTT​CCA​G-3′        141
                                             R            5′-TCC​TCA​CGC​ATA​AAC​AGC​TC-3′           
  *TMEM16B*              NM_153589           F            5′-TTT​ATG​ATT​GCC​CTG​ACG​TTC​TC-3′       141
                                             R            5′-GAG​GTT​GAT​GAT​GAC​TGC​TGT​T-3′        
  *Bestrophin 1*         NM_011913           F            5′-ACA​CAA​CAC​ATT​CTG​GGT​GC-3′           123
                                             R            5′-CGC​AAA​GTA​CAC​ACC​TCA​TTC​A-3′        
  *Bestrophin 2*         NM_001130194.1      F            5′-TCC​AGG​GCT​CCA​CCT​TTG​ATA​TAG-3′      101
                                             R            5′-AAA​GTC​CCC​GTG​AAC​CTC​TCC-3′          
  *CLCA1*                NM_017474           F            5′-GAA​ATT​CCC​CAG​CCC​TGT​AAC​AG-3′       144
                                             R            5′-TCG​GCA​CCT​GCT​CCG​TTA​TC-3′           
  *CLCA3A1*              NM_009899           F            5′-GTG​GAC​CAG​CCT​TTC​TAC​ATG​TCT​AG-3′   114
                                             R            5′-TGT​GAC​ACA​GTT​GCC​TCT​CTC​A-3′        
  NKCC1 *(Slc12a2)*      NM_009194           F            IDT Mm.PT.58.32659494                      131
                         R                                                                           
  NKCC2 *(Slc12a1)*      NM_001079690        F            IDT Mm.PT.58.29984258                      118
                         R                                                                           

List of all the primer sequences, their corresponding gene accession no. used for their design, and the predicted amplicon size. F, forward; R, reverse.

Western blot analysis {#s09}
---------------------

IALVs were dissected as described above, IALVs were pooled from two animals to generate one sample, and sections of brain and lung tissue were taken for positive controls. For protein extraction, IALVs were homogenized using a precooled pestle and mortar in 20 µl cold radioimmunoprecipitation assay buffer (RIPA) buffer plus 1% protease inhibitor cocktail (Sigma-Aldrich). The homogenate was incubated on ice for 30 min, and then sonicated for 1 min before removal of cellular debris with centrifugation at 8,000 *g* for 5 min at 4°C. The bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific) was used to determine protein concentration. Approximately 10--20 µg of total protein was incubated for 5 min at 90°C with freshly prepared 2× Laemmli buffer containing β-mercaptoethanol (5% vol/vol) and then loaded onto 4--20% TGX Precast Gels (Bio-Rad). Separated proteins were then transferred onto a polyvinylidene difluoride membrane (Bio-Rad) overnight at 4°C. The membranes were first probed with Rabbit Ano1 polyclonal antibody (1:1,000 dilution; 53212; Abcam) followed by anti-rabbit horseradish peroxidase--conjugated secondary antibody (1: 8,000 dilution; 65-6120; Thermo Fisher Scientific). Bound antibodies for Ano1 were detected using SuperSignal West Femto ECL Chemiluminescent Substrate (Thermo Fisher Scientific), and chemiluminescence signals were detected with a ChemiDoc XRS+ System (Bio-Rad).

### Immunofluorescence via confocal microscopy {#s10}

IALVs were cannulated, pressurized, and fixed with 4% paraformaldehyde for 45 min at room temperature. The IALVs were then washed with PBS and blocked overnight with 5% goat serum in PBS at 4°C. Next, the IALVs were incubated overnight in PBS with the corresponding primary antibodies: anti-SMA, 1:500 (A2547; Sigma-Aldrich), anti-GFP, 1:200 (A11122; Thermo Fisher Scientific), anti-Ano1 (SP31 ab64085; Abcam), or anti-Ano1, 1:100 (HPA032148; Sigma-Aldrich). IALVs were then washed with PBS and incubated overnight with the corresponding goat secondary antibodies (Thermo Fisher Scientific) at 1:200 or Avidin-Texas Red to stain mast cells. We reserved the Alexa Fluor 488--conjugated secondary antibodies for the corresponding anti-GFP primary antibody to prevent residual GFP fluorescence from confounding colocalization in IALVs isolated from mice with GFP expression (ROSA26mTmG and smMHC^Cre/eGFP^ mice). After a final wash, IALVs were recannulated and pressurized for imaging using an inverted Olympus IX81 microscope equipped with a Yokagawa spinning disk and Hamamatsu Orca Flash4 camera using an Olympus UPlanSApo 20× objective. Popliteal lymphatic vessels from Ano1-GFP mice were pressure fixed in a similar fashion and blocked for 3 h with 5% goat serum and stained overnight with anti-SMA conjugated to Cy3 (C6198; Sigma-Aldrich) and rabbit anti-GFP conjugated to AF488 (A-21311; Thermo Fisher Scientific). After washing, these vessels were imaged using an Olympus UApoN340 40× objective. Maximum z-stack projections were created with ImageJ from z-stacks taken at 1-micron intervals.

### Patch clamp protocols {#s11}

Conventional whole-cell voltage clamp was performed using single lymphatic muscle cells as determined by their morphology and/or GFP fluorescence upon dissociation. Pipettes were pulled from borosilicate glass and heat polished to 3--5 MΩ. For conventional whole-cell recording, the pipette solution contained (in mM) 126 CsCl, 10 HEPES, 10 d-glucose, 1 EGTA, 1 MgATP, 1 MgCl~2~, 0.2 GTP·Na, and 40 sucrose, with pH adjusted to 7.2 using CsOH. The pipette solution also contained either 0.7 mM or 0.9 mM CaCl~2~ to achieve 200 nM or 1 µM free Ca^2+^, respectively ([@bib50]). The bath solution contained (in mM) 126 N-methyl-d-glutamate Cl^−^, 10 HEPES, 10 d-glucose, 2 CaCl~2~, 1.2 MgCl~2~, and 40 sucrose, with pH adjusted to 7.4 using HCl ([@bib50]), and it constantly perfused the chamber. Currents were recorded using a patch-clamp amplifier (EPC-9; HEKA) and sampled at 20 kHz with analogue filtering at 6.67 kHz using a voltage ramp protocol from a holding potential of 0 mV and a voltage ramp from −100 mV to +80 mV over a period of 1 s. 1 µl of 10 mM benzbromarone was added to the 1 ml bath to achieve final concentration of 10 µM benzbromarone and ultimately allowed to wash out over a period of 5--10 min, and the ramp was repeated at each step unless the stability of the gigaseal was compromised. In some experiments, we added 1 µl of 1 mM nifedipine for a final concentration of 1 µM nifedipine to ensure L-type calcium activity did not confound our results. To study anion permeability, the conventional whole-cell configuration was used. Patch pipettes were initially dipped in pipette solution (in mM: 133 CsCl, 1 MgCl~2~, 0.5 EGTA, and 10 HEPES) and then backfilled. The bath solution was standard Hanks' balanced salt solution (135 Cl^−^) with sodium chloride substituted with sodium glutamate or sodium iodide to obtain (in mM) 49 Cl^−^ and 86 glutamate, or 125 I and 10 Cl^−^ ([@bib50]). To minimize the junction potentials, the reference Ag/AgCl electrode was immersed in a pipette solution continuous with an agar bridge (2% agar). All patch clamp experiments were analyzed using Pulse (HEKA) and Igor (Wave Metrics).

Pressure control {#s12}
----------------

Single IALV sections were then transferred to a 3-ml observation chamber, cannulated onto two glass micropipettes (30--80 µm, OD), pressurized to 3 cm H~2~O, and allowed to equilibrate to 37°C for 30 min. The cannulated IALV, with micropipette holders, observation chamber, and Burg-style V-track mounting system, was transferred to the stage of an inverted microscope (model IM-35; Zeiss). Polyethylene tubing was attached to each micropipette holder and connected to a valve that allowed pressure control to be switched between a manual reservoir and a servo-controlled pressure system ([@bib15]). Input and output pressures were set briefly to 8 cm H~2~O and the IALV lengthened to remove axial slack, which minimized lateral bowing and associated diameter-tracking artifacts at the higher pressures. A peristaltic pump maintained constant perfusion of the observation chamber with Krebs buffer at a rate of 0.5 ml/min while the IALV equilibrated at 37°C for 30--60 min with pressures set to 3 cm H~2~O. Spontaneous contractions typically began within 10 min and stabilized by 30 min. A Windows-based computer was used to digitize the pressure transducer signals and video image of the IALV (at 30--40 Hz) from a firewire camera ([@bib15]). A custom-written LabVIEW program (National Instruments) detected the inner diameter of the IALV from the video ([@bib14]).

Isolated IALV pressure myography {#s13}
--------------------------------

To test the response of each IALV to pressure, the input and output pressures were lowered simultaneously from 3 to 2, 1, and 0.5 cm H~2~O, then successively stepped to 1, 2, 3, 5, and 8 cm H~2~O. Under these conditions, there was no imposed pressure gradient for forward flow. Spontaneous contractions were recorded at each pressure for ∼2--3 min, and pressure was returned to 3 cm H~2~O after culmination of the pressure step protocol. For pharmacological inhibition of Ano1, benzbromarone was added from a 10 mM stock solution and mixed into the bath via pipetting to a final concentration of 7 µM and contractions allowed to stabilize. The perfusion pump was stopped for the duration of the benzbromarone experiment (7--10 min) to prevent dilution effects and the pressure steps to 2, 3, and 5 cm H~2~O were repeated. The IALV was then washed in Krebs buffer and the pressure steps repeated. To test the effects of genetic deletion of Ano1 from LMCs, control Ano1 f/fl, Ano1^smKO^, and c-KitCreER^T2^-Ano1KO IALVs were taken through the standard pressure step protocol. Some c-KitCreER^T2^-Ano1KO IALVs were also exposed to benzbromarone near the end of the pressure step protocol. Each experiment culminated with a 20-min equilibration in Ca^2+^-free Krebs and taken through the pressure steps to determine the passive diameter curve.

Myograph data analysis {#s14}
----------------------

After an experiment, custom-written analysis programs (LabVIEW) were used to detect peak end diastolic diameters, end systolic diameters, and contraction frequency, computed on a contraction-by-contraction basis over time in the 1--5-min period of time corresponding to each pressure level. The data were used to calculate several commonly reported contraction parameters:$$\begin{array}{l}
{\%~tone =} \\
{\left\lbrack {\left( \begin{array}{l}
{Max~Diameter~–~} \\
{End~Diastolic~Diameter} \\
\end{array} \right)/Max~Diameter} \right\rbrack*100,} \\
\end{array}$$$$Amplitude = \left( \begin{array}{l}
{End~Diastolic~Diameter~–~} \\
{End~Systolic~Diameter} \\
\end{array} \right),$$where Max Diameter represents the maximum passive diameter obtained in Ca^2+^-free Krebs solution at the same pressures at the end of the experiment.

V~m~ recordings and analysis {#s15}
----------------------------

IALVs were isolated and pressurized as described above. 2 µM wortmannin was applied to the perfusion bath for 30--60 min to inhibit myosin light chain kinase until contractions were blunted (\<5 µm contraction amplitude). Wortmannin has been consistently and routinely used to impair contractile activity without affecting the underlying electrical activity ([@bib17]). Impalements into lymphatic smooth muscle were made using intracellular microelectrodes (250--350 MΩ) filled with 1 M KCl, and V~m~ was sampled at 1 KHz using an SEC-05x amplifier (NPI) connected to a Grass S48 stimulator, viewed with a Tektronix TDS3052 digital oscilloscope, and recorded using a custom LabVIEW program. Thus, simultaneous recordings of diameter and V~m~ in pressurized and contracting IALVs were obtained. Once impaled, V~m~ was allowed to stabilize before action potentials and multiple contraction cycles were recorded for analysis. A lower concentration of benzbromarone was used in the V~m~ recording experiments (5 µM), as the higher concentration typically used in contraction studies (7 µM) routinely stopped all activity, which we suspected resulted from a cumulative effect of benzbromarone and wortmannin. In some cases, if an impalement was lost due either to mixing via pipetting or vessel movement during contraction or tone changes, attempts were made to reimpale the same cell, if possible, or a second cell in the immediate vicinity. Once recordings were completed, the electrode was retracted and the recording was corrected for the offset potential. Action potentials were processed automatically using an in-house Python algorithm to determine resting V~m~, diastolic depolarization, threshold V~m~, spike V~m~, plateau V~m~, and time over threshold ([@bib65]). For the initial linear diastolic depolarization phase of the action potential, the depolarization rate was obtained from a linear fit and expressed as mV/s. In the case of the fast-depolarization phase, the time-constant, τ (expressed in ms), from an exponential fit, V(t)=e^t/τ^, was calculated such that a low τ reflected a steeper curve. Membrane potential traces consisting of a minimum of three consecutive action potentials were analyzed under each condition, and the average value for each parameter was used to represent that for a single IALV.

Ca^2+^ imaging and analysis {#s16}
---------------------------

SMMHC-CreER^T2^-GCaMP6f mice were used as controls for SMMHC-CreER^T2^-GCaMP6f-Ano1KO mice. IALVs were dissected and pressurized as described above and placed in an observation chamber on an inverted Olympus IX-80 confocal microscope. Contractions were blunted with 2 µM wortmannin to prevent movement of the vessel out of focus in the z axis. Vessels were excited with a 488-nm laser and imaged at 20--50 frames per second using an electron multiplying charge-coupled device (EMCCD; Photometrics Cascade II 512) camera for 30--60 s. Sections on the periphery of image stacks that did not contain the vessel were used to determine background noise using the histogram function of ImageJ, which was then subtracted from the image stack. Maximum projections of the image stack were then used to create non-overlapping cell masks of three to five muscle cells per field of view of each vessel. Ca^2+^ traces for those cells contained 2--20 global Ca^2+^ flashes and were characterized for rise time, peak intensity (expressed as a baseline-referenced ratio, F/F~0~), duration (in seconds), and total integrated signal (area under the curve) per Ca^2+^ flash. These parameters were averaged across three to five cells from a single vessel to represent that vessel as a singular data point.

Solutions and chemicals {#s17}
-----------------------

Krebs buffer was composed of (in mM) 146.9 NaCl, 4.7 KCl, 2 CaCl~2~•2H~2~O, 1.2 MgSO~4~, 1.2 NaH~2~PO~4~•H~2~O, 3 NaHCO~3~, 1.5 NaHEPES, and 5 d-glucose, pH 7.4, at 37°C. Krebs-BSA buffer was prepared with the addition of 0.5% (wt/vol) BSA. During cannulation the luminal and bath solutions contained Krebs solution with BSA, but during the experiment, the bath solution was constantly exchanged with Krebs solution without albumin. For the Ca^2+^-free Krebs solution, 3 mM EGTA replaced CaCl~2~•2H~2~O. A benzbromarone stock solution was prepared at 10 mM in DMSO, separated into aliquots, and stored at −20°C for up to 2 mo. Doxycycline was prepared at 4 mg/ml in sterile saline and separated into aliquots, and frozen at −20°C until use. Tamoxifen was dissolved to 10 mg/ml in a safflower oil--ethanol (95/5% vol/vol) solution with rocking agitation, separated into aliquots, and stored at −20°C. Wortmannin was dissolved in DMSO to a stock solution of 10 mM. All chemicals were obtained from Sigma-Aldrich, with the exception of BSA (United States Biochemicals), and MgSO~4~ and NaHEPES (Thermo Fisher Scientific).

Statistical tests {#s18}
-----------------

Contraction frequency, amplitude, and tone at each pressure during the pressure step protocol were assessed via repeated measures two-way ANOVA with Dunnet's post hoc tests. Dose-dependent inhibition to benzbromarone was performed at a single pressure (3 cm H~2~O) and analyzed via repeated-measures one-way ANOVA. Patch clamp data were assessed through either a two-tailed *t* test or one-way ANOVA. V~m~ and Ca^2+^ recordings were assessed by two-tailed *t* test. Statistical significance was assumed at P \< 0.05 and indicated with \*. Values reported refer to means ± SEMs, and *n* can be found in each figure legend.

### Online supplemental material {#s19}

Fig. S1 contains representative immunofluorescence image of a IALV stained with 4\',6-diamidino-2-phenylindole, anti-Ano1, anti-SMA, and avidin. A sparse population of mast cells was observed in the adventitia of isolated IALVs as determined by avidin staining. While these mast cells were positive for Ano1, they did not account for the majority of the adventitial cells that stained strongly for Ano1.

Results {#s20}
=======

The CaCC Ano1 is expressed in mouse LMCs {#s21}
----------------------------------------

We detected Ano1 transcript through conventional RT-PCR in both isolated whole IALVs and freshly collected LMCs ([Fig. 1 A](#fig1){ref-type="fig"}), but we did not observe expression of its paralog Ano2 (also with CaCC activity, known as TMEM16b; [Fig. 1 B](#fig1){ref-type="fig"}; [@bib46]; [@bib47]). Western blots of whole lymphatic IALV confirmed the presence of Ano1 protein in both its apparent dimeric and monomeric forms ([Fig. 1 C](#fig1){ref-type="fig"}). Immunofluorescence protocols identified the cells that expressed Ano1 and revealed a diffuse staining pattern ([Fig. 1 D](#fig1){ref-type="fig"}) within SMA-positive LMCs ([Fig. 1, E and F](#fig1){ref-type="fig"}). This was also further confirmed with anti-GFP ([Fig. 1 H](#fig1){ref-type="fig"}) and anti-SMA ([Fig. 1 I](#fig1){ref-type="fig"}) staining of the muscle layer of a popliteal vessel from an Ano1-GFP reporter mouse ([Fig. 1 J](#fig1){ref-type="fig"}). Interestingly, anti-Ano1 staining also revealed a morphologically heterogeneous population of adventitial cells that were SMA-negative ([Fig. 1, F and J](#fig1){ref-type="fig"}) but stained strongly for Ano1. A subpopulation of these adventitial cells displayed a round morphology and could be costained with avidin, consistent with previous reports that nonmucosal mast cells express Ano1 (Fig. S1; [@bib8]).

![**Molecular evidence for Ano1 and CaCC current in LMCs.** Representative RT-PCR, resolved by agarose gel electrophoresis, for Ano1 (TMEM16a) (A) and TMEM16b (B) mRNA expression in lymphatic IALVs, LMCs, with lung and brain tissue as positive controls. **(C)** Western blot of collected IALVs and lung lysate with both the monomeric and dimer forms of Ano1 observed. Representative immunofluorescence maximal projection of an IALV stained anti-Ano1 (D) and with anti-SMA (E) to delineate Ano1 expression in LMCs (F, merge) at 20× objective magnification with the corresponding negative control (G). Representative immunofluorescence maximal projection of a popliteal lymphatic vessel isolated from an Ano1-GFP reporter mouse was stained with anti-GFP conjugated to AF488 (H) and anti-SMA conjugated to Cy3 (I) to further demonstrate LMC expression of Ano1 (J, merge).](JGP_201812294_Fig1){#fig1}

Murine LMCs display a functional I~ClCa~ {#s22}
----------------------------------------

Conventional whole-cell voltage clamp of freshly dispersed LMCs from IALV revealed a Cl^−^ current with amplitude sensitive to pipette Ca^2+^ concentration ([Fig. 2, A--C](#fig2){ref-type="fig"}). Under high Ca^2+^-PSS pipette buffer conditions, the majority of LMCs demonstrated an increased Cl^−^ current with a slight inward rectification profile ([Fig. 2 A](#fig2){ref-type="fig"}). The reversal potential of this current was −2.6 mV ± 0.9 under equivalent pipette and bath Cl^−^ concentrations, was shifted to −30.4 ± 11.5 mV when the bath solution containing 135 mM Cl^−^ was replaced with I^−^ 125 mM and 10 mM Cl^−^, and shifted to 23.4 ± 7.4 mV when Cl^−^ was replaced with 86 mM glutamate and 38 mM Cl^−^ ([Fig. 2, D and E](#fig2){ref-type="fig"}). These values closely approximate the theoretical reversal potentials of −30 mV and 26 mV expected for a pure Cl^−^ current ([@bib50]). We also ruled out Ca^2+^ entry through L-type calcium channels by repeating the voltage ramp protocol in the presence 1 µM nifedipine ([Fig. 2 F](#fig2){ref-type="fig"}) and found no significant differences in the recorded currents ([Fig. 2, G and H](#fig2){ref-type="fig"}).

![**IALV LMCs display a functional CaCC current. (A)** Representative recordings of whole cell patch clamp experiments designed to assess Cl^−^ current of freshly dissociated LMCs with either low Ca^2+^ (200 nM, black trace, *n* = 16 LMCs) or high Ca^2+^ (1 µM, red trace, *n* = 8 LMCs) in the patch pipette. Statistical analysis of current density at both −80 mV (B) and +80 mV (C). Representative traces showing current reversal potential with Krebs bath solution 135 mM Cl^−^ (*n* = 9) substituted with either glutamate (86 mM glutamate and 38 mM Cl^−^, *n* = 11) or iodide (125 mM I^−^ and 10 mM Cl^−^, *n* = 8). Representative raw traces in each buffer (D) and the summary data (E). Representative current trace in response to a voltage ramp protocol during conventional whole-cell patch clamp with or without 1 µM nifedipine present to block Ca^2+^ entry through L-type channels (F). A summary of recorded currents at −80 mV (G) and +80mV (H) with or without nifedipine (*n* = 8 cells). pA, picoamperes; pF, picofarad. \*, P \< 0.05.](JGP_201812294_Fig2){#fig2}

Ano1 has been associated with both the canonical I~ClCa~ and the bestrophin mediated cGMP-dependent I~ClCa~ observed in vascular smooth muscle ([@bib10]), and we tested whether the LMC I~ClCa~ was cGMP-dependent. RT-PCR confirmed the expression of Bestrophin1, but not Bestrophin2, transcript in whole IALV cDNA preparations ([Fig. 3 A](#fig3){ref-type="fig"}); however, LMC Cl^−^ currents were not potentiated by the cGMP analogue 8-br-cGMP (300 µM) nor inhibited by ZnCl~2~ (10 µM, [Fig. 3, B--D](#fig3){ref-type="fig"}) in contrast to what would be expected from bestrophin-mediated cGMP-sensitive Cl^−^ current. We also confirmed previous reports of messenger RNA (mRNA) expression of CLCA3A1 ([@bib19]; formerly designated mCLCA1) in the IALV extracts, likely derived from lymphatic endothelial cells, but failed to observe expression of CLCA1 ([Fig. 3 A](#fig3){ref-type="fig"}), whose orthologue in humans has been shown to modulate Ano1 activity ([@bib42]). We also detected the expression of the Na^+^K^+^Cl^−^ cotransporter (NKCC) 1 ([Fig. 3 E](#fig3){ref-type="fig"}), but not NKCC2 ([Fig. 3 F](#fig3){ref-type="fig"}), in purified IALV LMCs via RT-PCR.

![**The IALV LMC CaCC is not cGMP-dependent. (A)** Representative RT-PCR for bestrophin 1, bestrophin 2, CLCA1, and CLCA3 expression in IALV. **(B)** Representative Cl^−^ current density trace in response to a voltage ramp protocol during whole-cell conventional patch clamp of freshly dispersed IALV LMCs (*n* = 6), in response to stimulation with 300 nM 8-br-cGMP (*n* = 6), and 10 µM ZnCl~2~ (*n* = 4). Summary of current density at −80 mV (C) and +80 mV (D). Representative RT-PCR for NKCC1 (E) and KNCC2 (F) in IALVs and LMCs purified from IALVs with kidney extract as a positive control.](JGP_201812294_Fig3){#fig3}

Ano1 is required for LMC I~ClCa~ and IALV pressure-sensitive contraction frequency {#s23}
----------------------------------------------------------------------------------

After demonstrating functional I~ClCa~ in LMCs, we used the y chromosome--linked, tamoxifen-inducible, smooth muscle--targeted Cre mice (SMMHC-CreER^T2^) to delete Ano1 from LMCs to specifically test the role of Ano1 in the regulation of lymphatic pacemaking. We first tested the recombination efficiency of the SMMHC-CreER^T2^ in lymphatic muscle cells by crossing it to the fluorescent reporter ROSA26mT/mG and consistently observed \>95% recombination of the IALV LMC population using our induction protocol ([Fig. 4 A](#fig4){ref-type="fig"}). LMCs isolated from SMMHC-CreER^T2^-Ano1KO IALVs also had significantly reduced Cl^−^ current ([Fig. 5 A](#fig5){ref-type="fig"}), even with high pipette Ca^2+^, at both positive ([Fig. 5 B](#fig5){ref-type="fig"}) and negative membrane potentials ([Fig. 5 C](#fig5){ref-type="fig"}) when compared with Ano1fl/fl control LMCs. At the whole vessel level, full-length IALV pairs isolated from SMMHC-CreER^T2^-Ano1KO mice had a 60% reduction in Ano1 mRNA compared with Ano1fl/fl controls as determined by qPCR ([Fig. 5 D](#fig5){ref-type="fig"}) in SMMHC-CreER^T2^-Ano1KO mice. Presumably the residual Ano1 message came from endothelial cells or adventitial cells. Ano1fl/fl control IALVs maintained a typical contraction pattern in response to the pressure step protocol ([Fig. 5 E](#fig5){ref-type="fig"}). Strikingly, the contraction frequency of the SMMHC-CreER^T2^-Ano1KO IALV did not change with pressure over the course of the entire pressure range ([Fig. 5, F and G](#fig5){ref-type="fig"}, i.e., pressure-dependent contraction frequency was abolished, resulting in a significantly reduced contraction frequency compared with controls at all pressures tested. In contrast, there were no significant differences in contraction amplitude ([Fig. 5 H](#fig5){ref-type="fig"}) or tone ([Fig. 5 I](#fig5){ref-type="fig"}) at any pressure between vessels from Ano1fl/fl control mice and SMMHC-CreER^T2^-Ano1KO mice.

![**Recombination efficiency of SMMHC-CreER^T2^, SMArTTa-tetOCre, smMHC^Cre/eGFP^, and c-KitCreER^T2^ lines with ROSA26mT/mG**. **(A)** Representative immunofluorescence maximal projections of a fixed SMMHC-CreER^T2^-ROSA26mT/mG IALV stained for GFP and SMA to determine recombination efficiency. **(B)** Representative immunofluorescence maximal projections of a fixed SMArTTa-tetOCre-ROSA26mT/mG IALV stained with antibodies for GFP and SMA to determine recombination efficiency. **(C)** Representative immunofluorescence maximal projections of a smMHC^Cre/eGFP^ IALV fixed and stained for GFP and SMA to determine recombination efficiency. **(A--C)** Comparisons of cell masks for SMA and GFP to highlight cells that were SMA-positive/GFP-negative and the merged maximal projection used to assess recombination efficiency. **(D)** Representative immunofluorescence maximal projections of a live and pressurized (2 cm H~2~O) c-KitCreER^T2^-ROSA26mT/mG IALV imaged for GFP (recombined cells) and td-tomato (not recombined). Images were taken at 20× objective magnification. **(E)** Representative immunofluorescent images of the intestine muscle layer of a c-KitCreER^T2^-ROSA26mT/mG induced with our tamoxifen injection protocol and acquired using a fluorescence macroscope revealed recombination of the c-Kit^+^ interstitial cells of Cajal. RFP, red fluorescent protein (tdTomato); GFP, green fluorescent protein (EGFP).](JGP_201812294_Fig4){#fig4}

![**Inducible deletion of Ano1 from LMCs reduces contraction frequency and abrogates pressure-dependent contraction frequency. (A)** Representative trace of Cl^−^ current density during a voltage ramp protocol using conventional whole-cell patch clamp of freshly dispersed LMCs from IALV isolated from Ano1fl/fl (*n* = 8) or SMMHC-CreER^T2^-Ano1KO (*n* = 8) mice (1 µM Ca^2+^ in patch pipette). Summary of current density at −80 mV (B) and +80 mV (C). **(D)** Normalized Ano1 expression determined by qPCR from whole IALV in Ano1fl/fl controls (*n* = 5) and SMMHC-CreER^T2^-Ano1KO (*n* = 4) mice. 20-s clips from a single representative inner diameter trace over the pressure step protocol for an IALV isolated from the Ano1fl/fl controls (E) and the SMMHC-CreER^T2^-Ano1KO mice (F). Statistical summary of contractile parameters frequency (G), amplitude (H), and tone (I) at each pressure. \*, P \< 0.05 for SMMHC-CreER^T2^-Ano1KO (*n* = 27) versus Ano1fl/fl controls (*n* = 22).](JGP_201812294_Fig5){#fig5}

Loss of IALV pressure-dependent contraction frequency consistently observed in Ano1^smKO^ but not in c-KitCreER^T2^ in Ano1KO {#s24}
-----------------------------------------------------------------------------------------------------------------------------

To further confirm that the lack of pressure-dependent contraction frequency was not strain- or induction protocol--dependent, we used two other distinct smooth muscle targeted Cre lines, the doxycycline-inducible SMArTTa-tetOCre and the constitutive smMHC^Cre/eGFP^. Similar to SMMHC-CreER^T2^ IALVs, \>95% recombination was achieved with the SMArTTa-tetOCre with our doxycycline induction protocol, based on the ROSA26mT/mG reporter ([Fig. 4 B](#fig4){ref-type="fig"}). The GFP fluorescence of the constitutive smMHC^Cre/eGFP^ was also used as a surrogate of recombination efficiency, with typically 80% recombination observed ([Fig. 4 C](#fig4){ref-type="fig"}). However, in the constitutive smMHC^Cre/eGFP^ mice, both the number of GFP^+^ cells and endogenous GFP^+^ fluorescence signal were quite variable from mouse to mouse in contrast to the consistent results achieved with the inducible Cre lines, suggesting that the smMHC^Cre/eGFP^ transgene may have a low expression/penetrance in LMCs. Consistent with the contraction phenotype observed in SMMHC-CreER^T2^-Ano1KO IALVs, IALVs isolated from both the SMArTTa-tetOCre-Ano1KO and smMHC^Cre/eGFP^-Ano1KO mice had a significantly reduced contraction frequency that did not respond to changes in pressure. In all Ano1^smKO^ mice, contraction amplitude and tone were not significantly different from Ano1 fl/fl control vessels ([Fig. 6, B and C](#fig6){ref-type="fig"}). Lastly, Ano1 deletion did not seem to acutely affect LMC viability or turnover as the impairment in contraction frequency persisted for at least 4 mo after induction ([Fig. 6 A](#fig6){ref-type="fig"}).

![**IALV contractile parameters of all Ano1^smKO^ and c-KitCreER^T2^ Ano1KO**. Summary of IALV contractile parameters frequency (A), amplitude (B), and tone (C) from SMMHC-CreER^T2^-Ano1KO, SMArTTa-tetOCre-Ano1KO, and the constitutive smMHC^Cre/eGFP^-Ano1KO. Contractile parameters for SMArTTa-tetOCre-Ano1KO from two IALVs collected 4 mo after induction as opposed to 2 wk. \*, \#, and \$ denote P values \< 0.05 when compared with Ano1fl/fl controls (*n* = 22) for SMMHC-CreER^T2^-Ano1KO (*n* = 27), smMHC^Cre/eGFP^-Ano1KO (*n* = 7), and SMArTTa-tetOCre-Ano1KO (*n* = 6), respectively. Summary of IALV contractile parameters frequency (D), amplitude (E), and tone (F) from c-KitCreER^T2^-Ano1KO mice (*n* = 5) and Ano1fl/fl control mice (*n* = 22).](JGP_201812294_Fig6){#fig6}

In the intestinal tract, Ano1 is expressed almost exclusively within the c-Kit^+^ interstitial cells of Cajal that serve as pacemaking cells and whose slow wave activity is dependent on Ano1 ([@bib52]; [@bib30]; [@bib34]). We tested whether deletion of Ano1 from c-Kit^+^ cells in IALVs would alter lymphatic pacemaking. Using our tamoxifen induction protocol for the c-KitCreER^T2^-ROSA26mT/mG mice, we observed recombination only in a sparse population of morphologically round cells located in the adventitia and in a minor population of lymphatic endothelial cells ([Fig. 4 D](#fig4){ref-type="fig"}) despite robust labeling of interstitial cells of Cajal in the intestine of the same mice ([Fig. 4 E](#fig4){ref-type="fig"}). In contrast to the Ano1^smKO^ mice, IALVs isolated from c-KitCreER^T2^-Ano1KO did not have a significantly different contraction frequency, amplitude, or tone compared with the Ano1 fl/fl mice ([Fig. 6, D--F](#fig6){ref-type="fig"}).

Benzbromarone inhibits LMC I~ClCa~ and causes a dose-dependent inhibition of contraction frequency {#s25}
--------------------------------------------------------------------------------------------------

Ano1 deletion from smooth muscle cells consistently resulted in a loss of LMC I~ClCa~ and abrogated the pressure-dependent contraction frequency change in murine IALVs. However, deletion of Ano1 could possibly alter the activity of other channels from a loss of protein--protein-dependent interactions as has been described for bestrophins ([@bib11]) and cystic fibrosis transmembrane conductance regulator ([@bib2]) or from changes in channel expression as observed with L-type channels ([@bib11]). We used the potent Ano1 inhibitor benzbromarone ([@bib31]) to acutely test the role of Ano1-dependent I~ClCa~ of LMCs in the pressure-sensitive contraction frequency change of pressurized IALVs. Cl^−^ current recorded in LMCs using 200 nM Ca^2+^ pipette solution was significantly inhibited by 10 µM benzbromarone ([Fig. 7 A](#fig7){ref-type="fig"}) at both negative ([Fig. 7 B](#fig7){ref-type="fig"}) and positive voltages ([Fig. 7 C](#fig7){ref-type="fig"}) and was partially restored upon washout. As benzbromarone is a potent, but not selective, inhibitor of CaCCs ([@bib31]), we determined the benzbromarone dose-response relationship for pressurized IALVs ([Fig. 7 D](#fig7){ref-type="fig"}). Benzbromarone caused a significant, dose-dependent reduction in both contraction frequency ([Fig. 7 E](#fig7){ref-type="fig"}) and tone ([Fig. 7 G](#fig7){ref-type="fig"}), with a trend to reduce contraction amplitude at higher concentrations ([Fig. 7 F](#fig7){ref-type="fig"}), although the latter effect was not significant. Contractions ceased at 10 µM benzbromarone in at least half of the IALVs ([Fig. 7 D](#fig7){ref-type="fig"}), precluding its use in our contractile studies at doses ≥10 µM, as have been used in other studies ([@bib29]; [@bib31]; [@bib25]); whether this effect was due to Ano1 inhibition or an off-target effect could not be determined.

![**Inhibition of LMC I~ClCa~ and effect of benzbromarone dose-response on IALV contractile parameters. (A)** Representative trace of absolute Cl^−^ current during a voltage ramp protocol using conventional whole-cell patch clamp of freshly dispersed LMCs in response to the Ano1 inhibitor benzbromarone and after washout (200 nM Ca^2+^ in patch pipette). Summary of current density at −80 mV (B) and +80 mV (C). *n* = 23 LMCs for control and 10 µM benzbromarone; *n* = 10 LMCs whose patch integrity persisted through washout (D). Representative inner diameter trace of a WT IALV pressurized to 3 cm H~2~O in response different concentrations of benzbromarone (1, 3, 5, 7, and 10 µM). Summary of contractile parameters frequency (E), amplitude (F), and tone (G). \*, P \< 0.05 when compared with Krebs control with *n* = 4.](JGP_201812294_Fig7){#fig7}

Benzbromarone impairs pressure-dependent contraction frequency {#s26}
--------------------------------------------------------------

We then assessed the IALV contractile response at pressures 2--5 cm H~2~O using 7 µM benzbromarone. Representative diameter traces from a single IALV in Krebs buffer ([Fig. 8 A](#fig8){ref-type="fig"}) demonstrated a significant inhibition of contraction frequency with long pauses in diastole ([Fig. 8 B](#fig8){ref-type="fig"}) that reversed upon washout ([Fig. 8 C](#fig8){ref-type="fig"}). The effect of 7 µM benzbromarone was typically a single contraction (\*, [Fig. 8 B](#fig8){ref-type="fig"}) or two successive contractions (%, [Fig. 8 B](#fig8){ref-type="fig"}) followed by long pauses; however, a new rhythm at a lower contraction frequency was maintained, as opposed to producing a stochastic contraction pattern ([Fig. 8 B](#fig8){ref-type="fig"}). As observed in the dose--response plot, 7 µM benzbromarone caused a consistent and significant reduction in basal contraction frequency ([Fig. 8 D](#fig8){ref-type="fig"}) and tone ([Fig. 8 F](#fig8){ref-type="fig"}), but not contraction amplitude ([Fig. 8 E](#fig8){ref-type="fig"}). In the presence of benzbromarone, contraction frequency did not change during pressure elevation from 2 to 3 to 5 cm H~2~O. Both contraction frequency and tone recovered to their respective basal values upon benzbromarone washout. Last, 7 µM benzbromarone was able to impair the otherwise normal contractile frequency observed in c-KitCreER^T2^-Ano1KO mice ([Fig. 8 G](#fig8){ref-type="fig"}).

![**Lymphatic contractile function with the Ano1 inhibitor benzbromarone. (A--C)** Representative inner diameter trace from a single IALV during the pressure step protocol (A), and at pressures 2--5 cm H~2~O with 7 µM benzbromarone (B) and washout (C). **(B)** Both a single contraction (\^) or occasionally two consecutive contractions (%) were routinely observed in 7 µM benzbromarone. Statistical comparison of summary data for the contractile parameters frequency (D), amplitude (E), and tone (F). **(G)** Representative trace of c-KitCreER^T2^-Ano1KO IALV in response to 7 µM benzbromarone. \*, P \< 0.05 for benzbromarone versus Krebs with *n* = 7.](JGP_201812294_Fig8){#fig8}

Ano1 is a critical determinant of contraction frequency through modulation of the membrane potential diastolic depolarization rate {#s27}
----------------------------------------------------------------------------------------------------------------------------------

As each lymphatic contraction is preceded by an action potential, we used sharp electrode membrane potential recordings to assess the role of Ano1 in setting the LMC resting membrane potential and action potential initiation in pressurized, spontaneously contracting IALVs from Ano1 fl/fl and SMMHC-CreER^T2^-Ano1KO mice. Membrane potential recordings of Ano1fl/fl LMCs revealed action potentials at regular intervals underlying the IALV rhythmic contractile profile ([Fig. 9 A](#fig9){ref-type="fig"}). LMC membrane potential recordings in Krebs buffer ([Fig. 9 A](#fig9){ref-type="fig"}) demonstrated the typical characteristics of action potentials recorded in LMCs of pressurized IALVs ([@bib65]): a resting membrane potential that depolarized with a linear rate until reaching a critical threshold potential at approximately −29 mV, whereupon the depolarization increased exponentially, signifying the initiation of the action potential. We often observed an action potential "spike" of ∼2--5 mV in magnitude as calculated from the difference in the peak and plateau voltage. The time during which membrane potential was depolarized over the threshold potential (duration of the plateau) was ∼1.2--1.3 s. No significant after-hyperpolarization was observed during the repolarization phase of the action potential ([Fig. 9 A](#fig9){ref-type="fig"}). In contrast, action potentials recorded from SMMHC-CreER^T2^-Ano1KO mice had a distinctive change in action potential shape ([Fig. 9 B](#fig9){ref-type="fig"}) that accompanied the expected low, but still rhythmic, contraction frequency ([Fig. 9 C](#fig9){ref-type="fig"}). Resting membrane potentials were hyperpolarized in SMMHC-CreER^T2^-Ano1KO LMCs ([Fig. 9 D](#fig9){ref-type="fig"}), and the linear diastolic depolarization rate was significantly lower ([Fig. 9 E](#fig9){ref-type="fig"}). The threshold for action potential initiation remained unchanged ([Fig. 9 F](#fig9){ref-type="fig"}); however, the rapid upstroke was significantly steeper as demonstrated by a significantly lower exponential constant "τ" ([Fig. 9 G](#fig9){ref-type="fig"}). This was accompanied by a significantly more depolarized peak potential, around +10 mV in this representative IALV trace ([Fig. 9 B](#fig9){ref-type="fig"}) but as high as +20 mV in other IALVs ([Fig. 9 H](#fig9){ref-type="fig"}), that did not resolve into a plateau ([Fig. 9, B and I](#fig9){ref-type="fig"}). Instead, the SMMHC-CreER^T2^-Ano1KO action potential appeared to be a brief spike that quickly repolarized, resulting in approximately a 50% reduction in time spent over threshold potential as compared with the Ano1fl/fl controls ([Fig. 9 J](#fig9){ref-type="fig"}).

![**Sharp electrode LMC membrane potential recordings in pressurized IALV from Ano1fl/fl and SMMHC-CreER^T2^-Ano1KO mice**. Representative 10-s membrane potential recording made with sharp electrode impalements of an LMCs from pressurized IALVs isolated from an Ano1fl/fl control mouse (A) or SMMHC-CreER^T2^-Ano1KO mouse (B). The recorded action potentials were analyzed to assess action potential frequency (C), resting membrane potential (D), the linear diastolic depolarization rate (E), the action potential initiation threshold potential (F), the steepness of the action potential upstroke (G), peak voltage achieved during the action potential (H), the plateau voltage (I), and plateau duration (J). \*, P \< 0.05 comparing SMMHC-CreER^T2^-Ano1KO (*n* = 8) versus Ano1fl/fl (*n* = 11).](JGP_201812294_Fig9){#fig9}

The Ano1 inhibitor benzbromarone hyperpolarizes LMC resting V~m~ and decreases the diastolic depolarization rate to reduce contraction frequency {#s28}
------------------------------------------------------------------------------------------------------------------------------------------------

When membrane potential recordings were made in control vessels in Krebs buffer ([Fig. 10 A](#fig10){ref-type="fig"}), the application of 5 µM benzbromarone significantly reduced action potential frequency ([Fig. 10, B and C](#fig10){ref-type="fig"}). Resting membrane potential was significantly hyperpolarized ([Fig. 10 D](#fig10){ref-type="fig"}) by benzbromarone, and the diastolic depolarization rate was significantly reduced ([Fig. 10 E](#fig10){ref-type="fig"}). However, the threshold potential and exponential upstroke coefficient were unchanged by benzbromarone ([Fig. 10, F and G](#fig10){ref-type="fig"}). Furthermore, benzbromarone did not significantly alter the action potential peak potential ([Fig. 10 H](#fig10){ref-type="fig"}), the plateau potential ([Fig. 10 I](#fig10){ref-type="fig"}), or the duration of the action potential as measured by time spent over the threshold potential ([Fig. 10 J](#fig10){ref-type="fig"}).

![**Effect of the Ano1 inhibitor benzbromarone on sharp electrode LMC membrane potential of pressurized IALV.** Representative 20-s membrane potential recording made with sharp electrode impalement of a LMC from a pressurized IALV under control perfusion with Krebs solution (A) and in response to 5 µM benzbromarone (B). The recorded action potentials were analyzed to assess: action potential frequency (C), resting membrane potential (D), the linear diastolic depolarization rate (E), action potential initiation threshold potential (F), the steepness of the action potential upstroke (G), peak voltage achieved during the action potential (H), the plateau voltage (I), and plateau duration (J). \*, P \< 0.05 comparing 5 µM benzbromarone versus Krebs at *n* = 6.](JGP_201812294_Fig10){#fig10}

Ano1KO increases LMC action potential--driven Ca^2+^ flash peak intensity but reduces flash duration {#s29}
----------------------------------------------------------------------------------------------------

The activation of L-type calcium channels is required for the lymphatic action potential and is involved in determining the upstroke rate constant and duration of the plateau phase ([@bib65]). The significant reduction in the plateau duration and the altered action potential peak potential suggest involvement of another ion, and we hypothesized that the remaining action potential profile is the result of electrogenic Ca^2+^ influx through voltage-gated Ca^2+^channels. To test this hypothesis, we investigated the Ca^2+^ dynamics in IALVs from control SMMHC-CreER^T2^-GCaMP6f ([Fig. 11 A](#fig11){ref-type="fig"}) and SMMHC-CreERT2-GCaMP6f-Ano1KO mice ([Fig. 11 B](#fig11){ref-type="fig"}) using the genetically encoded Ca^2+^ sensor GCaMP6f. As previously described ([@bib65]), control IALV contractions are preceded by a near-synchronous global calcium event (calcium flash), with peak intensity 3--5-fold greater than baseline, lasting ∼1.5 s in each of the LMCs in the field of view; the flash corresponds with the action potential and reflects the influx of Ca^2+^ through LTCCs ([@bib65]). During diastole, spontaneous Ca^2+^ events were observed in most LMCs, but these were not coordinated between cells, and the Ca^2+^ signal ranged 30--50% over baseline ([@bib7]). In agreement with the contractile findings, the Ca^2+^ flash frequency was significantly reduced in SMMHC-CreER^T2^-GCaMP6f-Ano1KO mice ([Fig. 11 C](#fig11){ref-type="fig"}). As expected from changes in the action potential profile, peak Ca^2+^ flash intensity F/F~0~ was significantly higher ([Fig. 11 D](#fig11){ref-type="fig"}) in SMMHC-CreER^T2^-GCaMP6f-Ano1KO IALVs, with a significantly shorter time to reach peak Ca^2+^ ([Fig. 11 E](#fig11){ref-type="fig"}), but was also significantly shorter in duration ([Fig. 11 F](#fig11){ref-type="fig"}). Despite the shorter duration, SMMHC-CreER^T2^-GCaMP6f-Ano1KO IALVs had significantly greater Ca^2+^ entry as assessed by the area under the curve ([Fig. 11 G](#fig11){ref-type="fig"}) compared with SMMHC-CreER^T2^-GCaMP6f control IALVs.

![**Ca^2+^ flash analysis in pressurized IALV from SMMHC-CreER^T2^-GCaMP6f-Ano1KO mice.** Pressurized (3 cm H~2~O) control SMMHC-CreER^T2^-GCaMP6f (A) and SMMHC-CreERT2-GCaMP6f-Ano1KO (B) vessels were imaged at 20--33 fps with a 20× objective. Image sequences were made into maximum z-stack projections to create a single-cell mask to assess Ca^2+^ intensity over baseline (F/F~0~). Ca^2+^ flashes (\#) are indicative of action potential--generated Ca^2+^ influx through LTCCs, although spontaneous and local Ca^2+^ signals are also evident (\^). Summary data for Ca^2+^ flash frequency (C), peak Ca^2+^ intensity (D), time to reach peak Ca^2+^ (E), Ca^2+^ flash duration (F), and the area under the curve (G) were measured. \*, P \< 0.05 comparing SMMHC-CreER^T2^-Ano1KO versus Ano1fl/fl with *n* = 9 for control, *n* = 8 for SMMHC-CreER^T2^-Ano1KO.](JGP_201812294_Fig11){#fig11}

Discussion {#s30}
==========

The role for I~ClCa~ in the initiation of the lymphatic action potential has been suggested previously ([@bib54]; [@bib51]; [@bib1]; [@bib56]), although the identity of the critical ion channel(s) in LMCs has never been determined. Here we provide definitive evidence that the CaCC Ano1 is expressed within the LMCs of murine IALVs and is necessary for the pressure-dependent change in contraction frequency observed in lymphatic collecting IALVs. Ano1 is required for LMC I~ClCa~ and is a critical determinant of the lymphatic pacemaking by providing an excitatory current that sets the slope of the diastolic depolarization, the rate-limiting step in the initiation of an action potential. Deletion of Ano1 within the LMCs resulted in an altered action potential shape that also manifested in altered Ca^2+^ dynamics despite a normal contractile amplitude. The role of Ano1 in human lymphatic contractile regulation ([@bib38]) and the activity of Ano1 under pathological conditions warrant further investigation.

In the intestinal tract, Ano1 expression is almost exclusively confined to c-Kit^+^ interstitial cells of Cajal, including those located in the myenteric plexus that can be identified by their stellate morphology with widely branching processes ([@bib22]; [@bib30]; [@bib16]). In these pacemaker cells, Ano1 is critical to slow wave generation, effective pacemaking and coordination of intestinal smooth muscle contraction ([@bib30]; [@bib27]; [@bib34]). Recently, c-Kit^+^ adventitial cells were reported in the human lymphatic thoracic duct and regarded as interstitial cells of Cajal-like cells based on staining with methylene blue dye, transmission electron microscopy, and immunostaining for vimentin, CD34, and c-Kit ([@bib3]). In addition, c-Kit^+^ and vimentin^+^ cells have also been described in sheep mesenteric lymphatics ([@bib37]). However, our c-KitCreER^T2^-ROSA26mT/mG fluorescent reporter resulted in recombination of only a small population of large, round, adventitial cells (Fig. S1) on IALVs that we assume are mast cells based on their avidin^+^ staining profile, in agreement with previous reports ([@bib8]; [@bib24]). Additionally, recombination occurred in a very minor population of endothelial cells. In contrast to the sparse recombination of cells in the IALV, we could consistently observe significant recombination within the networks of interstitial cells of Cajal network of the small intestine using our induction protocol in c-KitCerER^T2^-ROSA26mT/mG mice ([Fig. 4 E](#fig4){ref-type="fig"}). A recent characterization of human dermal lymphatic vessels also failed to find a significant cell c-Kit^+^ cell population, aside from the observation of a round, granular population of c-Kit^+^ mast cells, and instead revealed adventitial cells positive for PDGFRα and CD34 ([@bib24]). A similar PDGFRα^+^CD34^+^ cell population may exist in the murine IALV wall and could also account for the strongly Ano1^+^ adventitial cells observed in our immunofluorescence images. The presence of a non-LMC Ano1^+^ cell population is further supported by the fact that whole-vessel Ano1 mRNA was reduced to only 40% of control levels in IALVs from SMMHCCreER^T2^-Ano1KO mice ([Fig. 5 D](#fig5){ref-type="fig"}) despite over 95% recombination in LMCs. Research into the identity of these non-LMC Ano1^+^ adventitial cells and whether they form electrical junctions with LMCs is ongoing, but the fact that they did not form a contiguous network argues against their role as pacemakers. The fact that LMCs express Ano1 and exhibit spontaneous calcium activity lends support to the hypothesis that LMCs act as their own intrinsic pacemaker.

Curiously, whole-cell Cl^−^ current recorded in LMCs demonstrated a slight inward rectification ([Fig. 1](#fig1){ref-type="fig"}). This contrasts with the majority of reports describing Ano1/TMEM16A voltage sensitivity ([@bib6]; [@bib46]; [@bib62]) with outward rectification that linearizes with increasing Ca^2+^ ([@bib6]; [@bib46]; [@bib62]), although some others report an almost linear I-V relationship ([@bib50]; [@bib5]). Our "low" Ca^2+^ 200-nM patch pipette concentration would be sufficient to partially activate Ano1 but does not explain why we observed slight inward rectification that persisted at higher patch pipette Ca^2+^ concentrations. Differences in the I-V curves could also be attributed to different cell systems and internal/external buffer composition. We used the same solutions, NMDG bath, and CsCl in the pipette as in the studies reporting more linear I-V profiles ([@bib50]; [@bib5]). Additionally, we also performed our ramp protocol in the presence of nifedipine to rule out a potentially confounding voltage-gated L-type Ca^2+^ current. The Cl^−^ currents we recorded were impaired with the Ano1 inhibitor benzbromarone ([Fig. 7 A](#fig7){ref-type="fig"}), one of the more potent inhibitors currently available ([@bib29]; [@bib31]), and were nearly absent in Ano1^smKO^ LMCs generated using two different Ano1fl/fl lines and two different inducible smooth muscle--targeting Cre mice; thus, the shape of the I-V curve is unlikely to be strongly influenced by the presence of another Cl^−^ channel. Critically, the reversal potentials recorded when Cl^−^ was substituted with either glutamate or iodide matched the theoretical values expected for a pure Cl^−^ current, ruling down a major contaminating influence of other ions and channels ([Fig. 1](#fig1){ref-type="fig"}). Notably, CaCC currents recorded in patch-clamped LMCs from sheep mesenteric lymphatic vessels also demonstrated a significant inward Cl^−^ current at negative membrane potentials that was blocked with the nonselective I~ClCa~ inhibitor 9-AC ([@bib51]). The disparity between the shape of the I-V curve for I~ClCa~ in LMCs and the I-V curve of Ano1 in vascular smooth muscle or heterologous expression systems could be due differences in the splice variant expressed ([@bib18]; [@bib48]), post-translational modifications to Ano1, the surrounding membrane environment ([@bib45]), or potential interactions with other proteins or channels, as documented for bestrophins ([@bib10]) and CFTR ([@bib2]). Through its interaction with bestrophins, Ano1 has also been implicated as a component of the cGMP-sensitive Cl^−^ current ([@bib10],[@bib11]), although we found no evidence for a cGMP-sensitive Cl^−^ current in the LMCs in this study ([Fig. 3, B--D](#fig3){ref-type="fig"}). The lack of cGMP-sensitive Cl^−^ current in mouse LMCs is unsurprising given the evidence for Cl^−^ in the initiation of lymphatic contractile activity compared with the predominantly inhibitory role of cGMP/PKG signaling reported in LMCs ([@bib21]; [@bib35]). Further investigations into the Ano1 splice variant expressed in lymphatic muscle and its possible interactions with other proteins within the LMC membrane are needed to resolve these issues.

The IALVs used for these studies have a relatively high baseline contractile frequency even at low pressures, in line with the findings of our recent study comparing the contractile activity of lymphatic collecting vessels from multiple tissues ([@bib65]). It is possible that regional differences in contractile frequency ([@bib20]; [@bib65]) can be attributed to different Ano1 expression or activity. In arteries/arterioles, Ano1 has been linked to the myogenic response through its contribution to depolarizing the resting membrane potential and thereby increasing LTCC activity, resulting in vasoconstriction as pressure rises ([@bib4]). We observed a significant reduction in tone with benzbromarone, but in contrast, found no significant differences in tone between Ano1^ismko^ and Ano1 floxed control mice. In addition to its ability to inhibit Ano1, benzbromarone has also been shown to act as an urate transporter inhibitor ([@bib32]) and as an activator of voltage-gated KQT-like subfamily potassium (KCNQ) channels ([@bib67]). These and other unknown off-target actions could explain the potent tone inhibition and cessation of contractions, achieved at higher benzbromarone concentrations, as neither observation was recapitulated in the Ano1^smKO^ IALVs even though the contraction frequency was almost identically reduced in both the Ano1^smKO^ and benzbromarone-treated vessels. The hyperpolarizations we observed with 5 µM benzbromarone and in Ano1^smKO^ IALVs were on the order of 4--6 mV, which may be insufficient to significantly alter lymphatic vessel tone. Additionally, or alternatively, there are likely to be contributing and potentially compensating actions of V~m~-independent mechanisms that regulate vessel tone through the balancing actions of myosin light chain kinases and phosphatases shown to be involved in lymphatic vessel tone maintenance ([@bib58]; [@bib40]).

As recently documented ([@bib65]), action potentials recorded in LMCs of pressurized murine IALVs are characterized by a slow, linear diastolic depolarization period that undergoes an exponential transformation upon reaching a critical voltage threshold to form the rapid upstroke of the action potential. A similar diastolic depolarization has been observed in rat and sheep vessels ([@bib1]; [@bib57]) with a suggested role for I~ClCa~. From our recordings, this slope is reduced nearly fourfold (from 7--8 mV/s to 2 mV/s) by deletion of Ano1 from the LMCs or by Ano1 inhibition with benzbromarone, suggesting a prominent role for Cl^−^ efflux in the determination of lymphatic pacemaking rate. Despite the significant reduction in contraction frequency and loss of pressure-dependent changes in contraction frequency, Ano1 does not appear to be obligatory for the initiation of the murine action potential, and other ion channels apparently contribute to the residual diastolic depolarization observed after Ano1 deletion. Other channels potentially involved in this basal diastolic depolarization could include voltage-gated sodium channels (Na~V~) channels, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, Piezo channels, and potentially mechanosensitive transient receptor potential (TRP) channels ([@bib36]; [@bib33]; [@bib49]). In the pacemaking interstitial cells of Cajal located in the myenteric plexus, the depolarizing action of Ano1 is set by intracellular Cl^−^, which accumulates through the action of NKCC1 ([@bib68]). The higher the intracellular concentration of Cl^−^, the more positive the Cl^−^ equilibrium potential (E~Cl~), which can allow for a depolarizing current through Cl^−^ efflux from the cell. Smooth muscle cells are known to express NKCC1 ([@bib59]), and we have observed expression of NKCC1 in purified LMCs from IALVs ([Fig. 3 E](#fig3){ref-type="fig"}), suggesting a similar axis is at play in the murine LMCs. This poses an interesting question as to whether the drugs furosemide and bumetanide, used as loop diuretics primarily through the inhibition of the NKCC2 isoform found in the kidney, but which also inhibit NKCC1, may inadvertently impair fluid removal out of the interstitial space through inhibition of LMC excitability. The roles of NKCC1 and LMC intracellular Cl^−^ concentration in the regulation of E~Cl~ in LMCs and their impact on the LMC diastolic depolarization warrant further examination.

The seminal work hypothesizing a role for I~ClCa~ was done in guinea pig mesenteric vessels, where spontaneous local Ca^2+^ events, termed puffs, were observed using fluorescent Ca^2+^ indicator dyes ([@bib54]; [@bib56]); these events were proposed to correlate with the spontaneous transient depolarizations observed in guinea pig mesenteric lymphatic vessels. The spontaneous transient depolarizations recorded in these preparations were sensitive to CaCC inhibitors, albeit inhibitors that do not distinguish well between cation and Cl^−^ channels ([@bib54]; [@bib56]). At a frame rate of 30 fps, we observed similar spontaneous Ca^2+^ signals ([Fig. 11](#fig11){ref-type="fig"}, \^ symbol) in the majority of LMCs in pressurized vessels expressing GCaMP6f in the LMC layer ([@bib65]); however, we did not consistently detect spontaneous transient depolarizations in membrane recording preparations sampled at 1 kHz. These differences may be explained in part by the conditions under which spontaneous transient depolarizations are primarily observed: (1) single vessels cut into small pieces in an attempt to achieve isoelectric conditions, (2) unpressurized and unstretched vessels from (3) guinea pig mesentery, and (4) during or after LTCC inhibition ([@bib54]; [@bib56]). Given the high degree of electrical coordination among lymphatic LMCs ([@bib7]; [@bib23]), it is possible that the local inward Cl^−^ current generated in response to a Ca^2+^ event rapidly dissipates across the electrically coupled length of our isobaric preparation and that the diastolic depolarization rate we observed is the integration of spontaneous transient depolarizations interacting with other voltage-sensitive channels ([@bib23]). Future studies combining both electrical and Ca^2+^ recordings in both single patch-clamped LMCs and whole vessels will be required to address these possibilities.

In addition to its role in action potential initiation, Ano1 activity makes a significant contribution to the duration and shape of the murine action potential, as the action potential plateau was absent in Ano1^smKO^ vessels. The murine IALV action potential often contains a brief 1--3-mV spike that approaches a potential of −5 mV before stabilizing at a sustained plateau potential around −11 to −10 mV ([@bib65]). The presence of this relatively small spike, as opposed to the larger spike observed in rat and human lymphatics ([@bib57]; [@bib49]), could be due to differences in voltage-gated sodium channel expression. In control IALVs, the duration of the LMC action potential plateau is significantly elongated by the L-type channel agonist BayK8644 ([@bib65]), while inhibition of L-type channels with nifedipine abolishes action potentials, leading to a static resting membrane potential ([@bib56]). In contrast, Ano1^smKO^ action potentials had peak potentials around +15 to +20 mV, lacked the plateau phase, and were shorter in duration, quickly repolarizing to a lower resting membrane potential than observed in controls ([Fig. 9](#fig9){ref-type="fig"}). We conclude from these findings that (1) Ano1 provides a baseline depolarizing current that contributes to resting membrane potential and diastolic depolarization; (2) upon reaching threshold, LTCCs open, resulting in an influx of Ca^2+^ that directly or indirectly (through Ca^2+^-induced Ca^2+^ release) activates Ano1; (3) the transition of the action potential spike into a plateau can be explained by the initial electrogenic Ca^2+^ influx from voltage-gated Ca^2+^ channels that quickly resolves into the plateau potential centered on E~Cl~ as Ano1 remains activated; and (4) action potential plateau duration is set by the combined action of Ano1 and LTCCs. These conclusions are further supported by the fact that the action potential exponential depolarization was steeper (a lower upstroke rate constant τ, [Fig. 9](#fig9){ref-type="fig"}) and the time to reach the peak Ca^2+^ flash was shorter in Ano1^smKO^ IALVs. The peak of the action potential was more positive and Ca^2+^ flash intensity was higher in Ano1^smKO^ IALVs, and both action potential duration and Ca^2+^ flash duration were shorter in the Ano1^smKO^ IALVs. The diffuse staining of Ano1 within the LMCs, as opposed to just localized puncta, further supports our interpretation that both local Ca^2+^ signals from the SR during the initiation of the action potential, and its associated global Ca^2+^ flash, can activate Ano1 channels. Additionally, the contribution of Ca^2+^ activated K^+^ channels (K~Ca~) and voltage-gated K^+^ channels (K~v~) channels to the murine lymphatic action potential are currently unknown and could be differentially involved in Ano1^smKO^ IALVs due to the altered Ca^2+^ and voltage dynamics. Additional studies using more selective pharmaceutical agents and/or KO mice are required to further understand and model the ionic components of the murine lymphatic action potential.

Lastly, despite the significant increase in peak Ca^2+^ and peak Ca^2+^ rise time, we did not observe any consistent or significant effect on contraction amplitude with Ano1 inhibition or in Ano1^smKO^ IALVs. In our recent report ([@bib65]), we demonstrated that the IALV contraction frequency was significantly reduced and contraction amplitude significantly increased with the LTCC agonist BayK8644. In that study, contraction frequency was reduced, not as a result of changes to the diastolic depolarization rate or the diastolic period, but due to a doubling in the duration of the action potential plateau phase ([@bib65]). It also is worth noting that plateau potential remained unchanged after BayK8644 stimulation ([@bib65]), providing further evidence that the murine lymphatic action potential is dominated by Cl^−^. While the contraction amplitude in WT IALVs increased with BayK8644, BayK8644 increased both the peak Ca^2+^ signal intensity and duration ([@bib65]); in contrast, Ano1^smKO^ IALVs had a significantly reduced Ca^2+^ flash duration, and the increase in peak flash Ca^2+^ was not as large as achieved with BayK8644-treated control vessels in our previous study ([@bib65]).

To circumvent the lethality associated with the Ano1^−/−^-null mice and to specifically target the lymphatic muscle cells, we used SMMHC-CreER^T2^ and SMArTTa-tetOCre lines that allowed us to direct the recombination to smooth muscle cells. This enabled us to specifically address the role of Ano1 in lymphatic muscle cells within our isolated vessel preparation. Despite the advantages offered by the inducible Cre mice, they are nonetheless limited by their induction and recombination efficiency and fidelity of the promoter in recapitulating the specific expression. We were unable to achieve 100% recombination in all LMCs with either of our inducible Cre lines SMMHC-CreER^T2^ and SMArTTa-tetOCre, based on our ROSA26mT/mG reporter. Furthermore, it is possible that Cre-directed recombination of ROSA26mT/mG does not equate to successful recombination of both Ano1 alleles in the Ano1^smKO^ mice. We attempted to use the constitutive smMHC^Cre/eGFP^ line to overcome the potential shortcomings of the induction efficiency inherent to inducible Cre models. Unfortunately, the smMHC^Cre/eGFP^ transgene was not visible in all LMCs, and the GFP^+^ LMCs were quite variable in their fluorescence intensity, implying a similar variability in Cre expression and recombination efficiency. We attribute the slightly higher average contraction frequency seen in the smMHC^Cre/eGFP^-Ano1KO IALVs to lower penetrance of the smMHC^Cre/eGFP^ within the lymphatic muscle layer, limiting the usefulness of this Cre line in future lymphatic studies. We have also yet to see any gross manifestations of lymphedema within the mouse limbs in smMHC^Cre/eGFP^-Ano1^smKO^ mice within our colony up to 1 yr despite the reduction in contraction frequency. However, the manifestation of lymphedema due to lymphatic contractile dysfunction in mice may require a chronic gravitational load ([@bib7]). Deletion of Ano1 has been shown to reduce the expression of LTCCs in vascular smooth muscle ([@bib11]); however, we did not observe any significant impairment in contraction amplitude, which is sensitive to LTCC inhibition. It is possible that a reduction in contraction amplitude due to a reduction in L-type calcium channels could be observed at a later time point.

Conclusions {#s31}
-----------

Ano1 is functionally expressed in LMCs and accounts for the majority, if not the totality, of the I~ClCa~ in LMCs. Ano1-mediated Cl^−^ current is critical for pressure-dependent modulation of contraction frequency of murine lymphatic vessels through its role in setting the resting membrane potential and diastolic depolarization rate, but Ano1 deletion from LMCs does not eliminate spontaneous contractions. Ano1 is likely activated in response to both spontaneous Ca^2+^ release from the SR and Ca^2+^ influx through LTCCs in mouse lymphatic muscle. Further investigations into the pressure-dependent mechanism of Ano1 activation during diastole are warranted.
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